Ann: Botanix Presents at Fall Clinical Dermatology Conference, page-50

Further to NZ Trader's comment, please note that BTX1503 is registered as an IND and as such the trial is being monitored by a FDA's review team:
From the FDA website, with my emphasis for argument' sake:

"FDA IND Review Team
The review team consists of a group of specialists in different scientific fields. Each member has different responsibilities.

• Project Manager: Coordinates the team’s activities throughout the review process, and is the primary contact for the sponsor.
• Medical Officer: Reviews all clinical study information and data before, during, and after the trial is complete.
• Statistician: Interprets clinical trial designs and data, and works closely with the medical officer to evaluate protocols and safety and efficacy data.
• Pharmacologist: Reviews preclinical studies.
• Pharmakineticist: Focuses on the drug’s absorption, distribution, metabolism, and excretion processes.Interprets blood-level data at different time intervals from clinical trials, as a way to assess drug dosages and administration schedules.
• Chemist: Evaluates a drug’s chemical compounds. Analyzes how a drug was made and its stability, quality control, continuity, the presence of impurities, etc.
• Microbiologist: Reviews the data submitted, if the product is an antimicrobial product, to assess response across different classes of microbes.mce-anchor"

https://www.fda.gov/forpatients/approvals/drugs/ucm405622.htm#FDA_IND_Review_Team

I could be wrong, but I don't think that reviewed trial' s data is then shared with the sponsor as it goes (for leaking?), rather it's more a case of no news being actually good news (so far no one got sick by taking part) and that the 'fire sale' as to do with the panic seizing the market. (I could be wrong while wrongly accumulating - so do your own research as I 'd hate to pass for a spruiker).